ArticleJournal of bioenergetics and biomembranes2025
Early cardioprotective effects of SGLT2i on hypertensive cardiac remodeling via STIM1/Orai1-dependent calcium signaling: beyond blood pressure control.
Article in Journal of bioenergetics and biomembranes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Dual Inhibition of the Renin-Angiotensin-Aldosterone System and Sodium-Glucose Cotransporter-2: Mechanistic and Clinical Evidence for Cardiorenal Protection.Biomedicines · 2026Review
- SGLT2 inhibitors and diabetic retinopathy progression: evidence from a retrospective cohort study and Mendelian randomization analysis.Frontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The cardioprotective effects of sodium-glucose cotransporter-2 inhibitors (SGLT2i) have attracted significant attention. The calcium ion signaling pathway influences various aspects of cellular function, store-operated calcium channels (SOCCs) serve as key calcium ion channels that induce cell apoptosis and exacerbate cardiac remodeling. This study aims to investigate the effects of SGLT2i on SOCCs and its potential cardioprotective mechanisms. Sprague-Dawley (SD) rats were sequentially treated with angiotensin II (Ang II) and dapagliflozin (Dapa), randomly divided into four groups: Sham, Dapa, Ang II, and Ang II + Dapa. Blood pressure, cardiac structure and function were measured. Cardiac fibrosis evaluated using Masson's trichrome staining. The apoptosis rate of H9C2 cells was determined by flow cytometry. Protein expression levels and functional activity of SOCCs were analyzed using Western blotting, calcium imaging, and fluorescence co-localization staining. In Ang II-induced hypertension rats, no significant blood pressure lowering effect of Dapa was observed within 28 days. Notably, the absence of blood pressure reduction did not affect the timely improvement of Ang II-induced cardiac remodeling by Dapa. Ang II enhanced store-operated calcium entry (SOCE), subsequently promoting cardiomyocyte apoptosis. Dapa administration effectively suppressed this pathological process by inhibiting the overexpression and overactivation of SOCC. SGLT2i improved early cardiac remodeling induced by Ang II without relying on antihypertensive effects, mainly by inhibiting excessive activation of SOCE, which effectively attenuated Ang II-triggered cardiomyocyte apoptosis. This provides a novel therapeutic paradigm targeting impaired myocardial calcium handling in hypertensive heart disease management.
Indexed as
Identifiers
40719970What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.